July launch by Stereotaxis achieves 70 cases treating full arrhythmia spectrum

July launch by Stereotaxis achieves 70 cases treating full arrhythmia spectrum
Stereotaxis treats 70 since July

Stereotaxis has treated 70 patients with arrhythmia since the program launch in July, reaching individuals across the full spectrum of arrhythmias, including those with histories of multiple failed procedures.

The company noted strong early demand and patient impact after a short period of service. Stereotaxis' technological innovations continue to expand access to advanced cardiac treatments.

Stereotaxis recently broadened its technology portfolio with the launch of the MAGiC ablation tip, designed for efficient energy delivery. The company has also experienced rising activity in robotic electrophysiology, as detailed in a previous update on sector momentum and expected growth. These developments align with ongoing efforts to improve treatment options for cardiac arrhythmia patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.